Skip Navigation
Search Menu
Find an Expert

 


Emmanuel Stylianos Antonarakis, M.B.B.Ch.

Photo of Dr. Emmanuel Stylianos Antonarakis, M.B.B.Ch.

Associate Professor of Oncology

Male

Languages: English, French, Greek

Expertise: Bladder Cancer, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology, Urology

Research Interests: Prostate Cancer

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-502-3823
Fax: 410-502-1419

Background

Dr Antonarakis is an Associate Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He obtained his medical degree from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. In 2010, he joined the Johns Hopkins faculty as an attending physician and translational researcher. Dr Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies (cancers of the bladder, kidney and testis).

His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 biomarker. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 110 peer-reviewed articles, and several book chapters.

 

...read more

Titles

  • Associate Professor of Oncology
  • Associate Professor of Urology

Departments / Divisions

Education

Degrees

  • MBBCh, University of Wales (2003)

Residencies

  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2007)
  • American Board of Internal Medicine / Medical Oncology (2009)

Additional Training

  • Physician License, State of Maryland (2007)

Research & Publications

Research Summary

Dr. Antonarakis is an Associate Professor of Oncology and Urology with an interest in genitourinary cancers and a particular focus on prostate cancer. He is an expert in the clinical management of patients with prostate cancer and other urological malignancies.

His research focuses on therapy development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 marker. He is currently the Principal Investigator of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 110 peer-reviewed articles, and several book chapters.

Lab

AR-V7 biomarker

Clinical Trial Keywords

Prostate Cancer

Clinical Trials

Phase II and III clinical trials in prostate cancer

Selected Publications

Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with non-metastatic prostate cancer treated with hormone therapy: a quantitative systematic review. Journal of Clinical Oncology 2007; 25: 4998-5008.

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. Journal of Clinical Oncology 2009; 27: 4986-4993.

Keizman D, Zahurak M, Sinibaldi V, Carducci MA, Denmeade S, Drake C, Pili R, Hudock S, Antonarakis ES, Eisenberger MA. Lenalidomide in non-metastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded randomized study. Clinical Cancer Research 2010; 16: 5269-5276.

Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters 2010; 291: 1-13.

Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG. Long-Term overall survival and metastasis-free survival for men with PSA-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research (CPDR) national database. BJU International 2011; 108: 378-385.

Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Walczak J, Kim JJ, Carducci MA, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. The Prostate 2011; 71: 1608-1615.

Keizman D, Huang P, Eisenberger MA, Pili R, Kim J, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. European Journal of Cancer 2011; 47: 1955-1961.

Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. New England Journal of Medicine 2011; 364: 2055-2058.

Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: long-term follow-up. BJU International 2012; 109: 32-39.

Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically-recurrent prostate cancer. The Prostate 2012; 72: 487-498.

Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with non-hormonal agents: combined analysis of 4 phase II trials. Cancer 2012; 118: 1533-1542.

Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemotherapy and Pharmacology 2012; 69: 763-771.

Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of two doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically-recurrent hormone-naïve prostate cancer: a DOD/PCF study. Urologic Oncology 2013; 31: 581-588.

Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063-6071.

Goyal J, Nuhn P, Huang P, Tyagi P, Oh D, Carducci MA, Eisenberger MA, Antonarakis ES. The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU International 2012; 110: E575-E582.

Antonarakis ES, Heath EI, Smith D, Rathkopf D, Blackford A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA. Repurposing itraconazole as a treatment for prostate cancer: A non-comparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013; 18: 163-173.

Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison M, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MR, Dyster LM, Carducci MA. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 2013; 71: 883-892.

Carvalho FL, Simons B, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, Matsui W, Berman DM. Tumorigenic potential of circulating prostate tumor cells. Oncotarget 2013; 4: 413-421.

Schweizer MT, Zhou X, Wang H, Yang T, Shaukat F, Partin A, Eisenberger MA, Antonarakis ES. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of Oncology 2013; 24: 2881-2886.

Paller CJ, Antonarakis ES. Management of biochemically-recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clinical Advances in Hematology & Oncology 2013; 11: 14-23.

Antonarakis ES, Eisenberger MA. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: Time to learn from past experiences. Journal of Clinical Oncology 2013; 31: 1709-1712.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically-recurrent prostate cancer. Prostate Cancer and Prostatic Diseases 2014; 17: 28-33.

Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer and Prostatic Diseases 2014; 17: 57-63.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett B, Wang H, Luber B, Alani R, Antonarakis ES, Azad N, Bardelli A, Brem H, Cameron J, Lee C, Fecher L, Gallia G, Gibbs P, Le D, Giuntoli R, Goggins M, Hogarty M, Holdhoff M, Hong S, Jiao Y, Juhl H, Kim J, Siravegna G, Laheru D, Lauricella C, Lim M, Lipson E, Marie S, Netto G, Oliner KS, Olivi A, Olsson L, Riggins G, Sartore-Bianchi A, Schmidt K, Shih I, Oba-Shinjo S, Siena S, Theodorescu D, Tie J, Harkins T, Veronese S, Wang T, Weingart J, Wolfgang C, Wood L, Xing D, Hruban R, Wu J, Allen P, Schmidt C, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine 2014; 6: 224ra24.

Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, Antonarakis ES. Association of pretreatment neutrophil-to-lymphocyte ratio and overall survival in patients with metastatic castration-resistant prostate cancer treated with first-line docetaxel. BJU International 2014; 114: E11-E17.

Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European Urology 2014; 66: 646-652.

Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer 2015; 13: 32-38.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. The Prostate 2014; 74: 1278-1285.

Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CS, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci M, Force T, Kelly WK. A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by rising PSA. American Journal of Cancer Therapy and Pharmacology 2014; 2: 21-32.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. The Prostate 2014; 74: 1560-1568.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine 2014; 371: 1028-1038.

Antonarakis ES, Nakazawa M, Luo J. Resistance to androgen-pathway drugs in prostate cancer. New England Journal of Medicine 2014; 371: 2233-2234.

Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of four phase-2 trials. Prostate Cancer and Prostatic Diseases 2015; 18: 49-55.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Science Translational Medicine 2015; 7: 269ra2.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman H, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer and Prostatic Diseases 2015; 18: 122-127.

Szabo Z, Mena E, Rowe SP, Plyku D, Nadal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG. Initial Evaluation of 18F-DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Molecular Imaging and Biology 2015; 17: 565-574.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A phase I study of muscadine grapeskin extract in men with biochemically-recurrent prostate cancer: Safety, tolerability, and dose-determination. The Prostate 2015; 75: 1518-1525.

Antonarakis ES. Predicting treatment response in castration-resistant prostate cancer: Could androgen receptor variant-7 hold the key? Expert Review of Anticancer Therapy 2015; 15: 143-145.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology 2015; 1: 582-591.

Yu SH, Zheng Q, Esopi D, Macgregor-Das A, Luo J, Antonarakis ES, Drake CG, Vessella R, Morrissey C, De Marzo AM, Sfanos KS. A paracrine role for IL-6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells. Cancer Immunology Research 2015; 3: 1175-1184.

Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of Oncology 2015; 26: 1859-1865.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. The Prostate 2015; 75: 1814-1820.

Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY. Comparison of PSMA-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-sensitive and castration-resistant metastatic prostate cancer. Journal of Nuclear Medicine 2016; 57: 46-53.

Teply BA, Luber B, Denmeade SR, Antonarakis ES. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 2015; epub ahead of print (doi:10.1038/pcan.2015.53).

Antonarakis ES, Luo J. AR splice variant dimerization–clinical implications. Nature Reviews Urology 2015; 12: 431-33.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. A phase II trial of ganetespib, a heat shock protein 90 (Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer – a Prostate Cancer Clinical Trials Consortium (PCCTC) study. Investigational New Drugs 2015; epub ahead of print (doi: 10.1007/s10637-015-0307-6).

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade S, Carducci MA, Eisenberger MA. Prognostic factors for clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. The Prostate 2015; epub ahead of print (doi: 10.1002/pros.23141).

Suzman DL, Antonarakis ES. Clinical implications of Hedgehog pathway signaling in prostate cancer. Cancers 2015; 7: 1983-1993.

Schweizer MT, Antonarakis ES. Liquid biopsy: Clues on prostate cancer drug resistance. Science Translational Medicine 2015; 7: 312fs45.

Maughan BL, Antonarakis ES. Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer. Current Treatment Options in Oncology 2015; 16: 57-70.

Patents

Multiple novel androgen receptor variants as biomarkers and therapeutic targets for androgen-refractory human prostate cancer
Patent # C10305

Methods and compositions related to prostate cancer therapeutics
Patent # C13126

Activities & Honors

Honors

  • ASCO Young Investigator Award (2009), ASCO, 2009
  • PCF Young Investigator Award (2013), Prostate Cancer Foundation (PCF), 2013
  • SBUR/AUA Young Investogator Award (2015), Society for Basic Urologic Research of the AUA, 2015

Memberships

  • American Medical Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research (AACR)
  • Eastern Cooperative Oncology Group (ECOG)
  • Prostate Cancer Clinical Trials Consortium (PCCTC)
  • Society for Basic Urologic Research (SBUR) of the AUA
Is this you? Edit Profile